Table 1. Clinical Details of the... | American Society of Hematology

Table 1.

Clinical Details of the Patients Included in This Study

Patient	Time from Diagnosis (mo)	Disease Status	WBC × 10⁶/mL^*	Previous Treatment	Current Treatment
G.H.	50	CML-CP	6.5	IFN-α, ABMT	IFN-α
K.D.	14	CML-CP	4.1	HU, IFN-α	HU
M.R.	12	CML-CP	20	HU, IFN-α	None
M.B.U.	3	CML-CP	4.9	HU	HU
M.B.A.	10	CML-CP	3.4	HU	HU
S.T.	2	CML-CP	40	HU, IFN-α	IFN-α
L.C.	1	CML-CP	90	None	None
A.Z.	18	CML-BC	40	HU, IFN-α	HU, IFN-α
P.S.	9	CML-CP	14	HU, IFN-α	HU
R.D.	36	CML-CP	21	HU, IFN-α, ICE	None
S.S.	3	CML-CP	12.5	HU	HU
R.G.	18	CML-BC	160	IFN-α, HU	HU
G.T.	39	CML-CP	51	IFN-α, HU	HU

Patient	Time from Diagnosis (mo)	Disease Status	WBC × 10⁶/mL^*	Previous Treatment	Current Treatment
G.H.	50	CML-CP	6.5	IFN-α, ABMT	IFN-α
K.D.	14	CML-CP	4.1	HU, IFN-α	HU
M.R.	12	CML-CP	20	HU, IFN-α	None
M.B.U.	3	CML-CP	4.9	HU	HU
M.B.A.	10	CML-CP	3.4	HU	HU
S.T.	2	CML-CP	40	HU, IFN-α	IFN-α
L.C.	1	CML-CP	90	None	None
A.Z.	18	CML-BC	40	HU, IFN-α	HU, IFN-α
P.S.	9	CML-CP	14	HU, IFN-α	HU
R.D.	36	CML-CP	21	HU, IFN-α, ICE	None
S.S.	3	CML-CP	12.5	HU	HU
R.G.	18	CML-BC	160	IFN-α, HU	HU
G.T.	39	CML-CP	51	IFN-α, HU	HU

*WBC day CIK cultured started.

Abbreviations: CML-CP, chronic-phase CML; ABMT, autologous bone marrow transplant; CML-BC, blast crisis CML; HU, hydroxyurea; ICE, idarubicin, cytosine arabinoside, etoposide; WBC, white blood cell.

View Large

This Feature Is Available To Subscribers Only